Perioperative Chemoimmunotherapy with Toripalimab for Sinonasal Cancer

Dana Farber is investigating a novel perioperative regimen combining toripalimab with docetaxel and carboplatin preceding surgery for resectable sinonasal cancers, including undifferentiated carcinoma and squamous cell carcinoma. The study also explores postoperative strategies—radiation with toripalimab or radiation (±cisplatin)—to optimize treatment based on pathological response, potentially enhancing long-term outcomes.